Liver disease meeting hears updates on Merck & Co's boceprevir, Boehringer Ingelheim's HCV combo, Vertex' telaprevir and Gilead's Viread
The American Association for the Study of Liver Disease, currently taking place in Boston, heard final results from US drug giant Merck & Co (NYSE: MRK) from two pivotal Phase III studies, HCV RESPOND-2 and HCV SPRINT-2 demonstrated that addition of boceprevir to the combination therapy of Pegintron (peginterferon alfa-2b) and Rebetol (ribavirin) achieved significantly higher sustained virologic response in adult chronic HCV genotype 1 patients, who previously failed treatment, and in adult patients who were new to treatment, compared to control arm.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze